HLA-B27 misfolding: A solution to the spondyloarthropathy conundrum?

Molecular Medicine Today

Volumn 6, Issue 6, 2000, Pages 224-230

  Colbert, Robert A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B27 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN FOLDING; PROTEIN STRUCTURE; REVIEW; SPONDYLOARTHROPATHY;

EID: 0034214169     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(00)01699-3     Document Type: Note

References (46)

1. Khan A. Ankylosing spondylitis: clinical aspects. Calin A., Taurog J.D. The Spondyloarthritides. 1998;27-40 Oxford University Press.
2. Wordsworth P. Genes in the spondyloarthropathies. Rheum. Dis. Clin. North Am. 24:1998;845-863.
3. Brewerton D.A.et al. Ankylosing spondylitis and HL-A 27. Lancet. 1:1973;904-907.
4. Schlosstein L.et al. High association of an HL-A antigen, W27, with ankylosing spondylitis. New Engl. J. Med. 288:1973;704-706.
5. Lopez-Larrea C.et al. The role of HLA-B27 polymorphism and molecular mimicry in spondyloarthropathy. Mol. Med. Today. 4:1998;540-549.
6. Ringrose J.H. HLA-B27 associated spondyloarthropathy, an autoimmune disease based on crossreactivity between bacteria and HLA-B27? Ann. Rheum. Dis. 58:1999;598-610.
7. Parham P. Presentation of HLA class I-derived peptides: potential involvement in allorecognition and HLA-B27-associated arthritis. Immunol. Rev. 154:1996;137-154.
8. Whelan M.A., Archer J.R. Chemical reactivity of an HLA-B27 thiol group. Eur. J. Immunol. 23:1993;3278-3285.
9. Laitio P.et al. HLA-B27 modulates intracellular survival of Salmonella enteritidis in human monocytic cells. Eur. J. Immunol. 27:1997;1331-1338.
10. Ikawa T.et al. Expression of arthritis-causing HLA-B27 on Hela cells promotes induction of c-fos in response to in vitro invasion by Salmonella typhimurium. J. Clin. Invest. 101:1998;263-272.
11. Mear J.P.et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J. Immunol. 163:1999;6665-6670.
12. Kostyu D.D.et al. HLA class I polymorphism: Structure and function and still questions. Hum. Immunol. 57:1997;1-18.
13. Rammensee H-G.et al. Peptides naturally presented by MHC class I molecules. Ann. Rev. Immunol. 11:1993;213-244.
14. Khan M.A. HLA-B27 polymorphism and association with disease. J. Rheumatol. 27:2000;1110-1114.
15. Gonzalez S.et al. Immunogenetics, HLA-B27 and spondyloarthropathies. Curr. Opin. Rheumatol. 11:1999;257-264.
16. Colbert R.A.et al. Allele-specific B pocket transplant in class I major histocompatibility complex protein changes requirement for anchor residue at P2 of peptide. Proc. Natl. Acad. Sci. U. S. A. 90:1993;6879-6883.
17. Colbert R.A.et al. Differences in peptide presentation between B27 subtypes: the importance of the P1 side chain in maintaining high affinity peptide binding to B*2703. Immunity. 1:1994;121-130.
18. Boisgerault F.et al. Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants. J. Clin. Invest. 989:1996;2764-2770.
19. Griffin T.A.et al. Naturally occurring A pocket polymorphism in HLA-B*2703 increases the dependence on an accessory anchor residue at P1 for optimal binding of nonamer peptides. J. Immunol. 159:1997;4887-4897.
20. Fiorillo M.T.et al. Susceptibility to ankylosing spondylitis correlates with the C-terminal residue of peptides presented by various HLA-B27 subtypes. Eur. J. Immunol. 27:1997;368-373.
21. Brooks J.M.et al. HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex. J. Immunol. 161:1998;5252-5259.
22. Lamas J.R.et al. Modulation at multiple anchor positions of the peptide specificity of HLA-B27 subtypes differentially associated with ankylosing spondylitis. Arthritis Rheum. 42:1999;1975-1985.
23. Yamaguchi A.et al. Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients: Evidence for a role of the peptide-anchoring B pocket. Arthritis Rheum. 38:1995;1672-1677.
24. Gonzalez-Roces S.et al. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens. 49:1997;116-123.
25. Brown M.A.et al. Ankylosing spondylitis in West Africans - evidence for a non-HLA-B27 protective effect. Ann. Rheum. Dis. 56:1997;68-70.
26. Taurog J.D.et al. Inflammatory disease in HLA-B27 transgenic rats. Immunol. Rev. 169:1999;209-223.
27. 2m-deficient mice occurs in the absence of HLA-B27 and is strain dependent. Arthritis Rheum. 41:1998;S346.
28. Khare S.D.et al. Animal models of human leukocyte antigen B27-linked arthritides. Rheum. Dis. Clin. North Am. 24:1998;883-894.
29. Pamer E., Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Ann. Rev. Immunol. 16:1998;323-358.
30. Hughes E.A.et al. Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. Proc. Natl. Acad. Sci. U. S. A. 94:1997;1896-1901.
31. Wiertz E.J.H.J.et al. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature. 384:1996;432-438.
32. Peace-Brewer A.L.et al. A point mutation in HLA-A*0201 results in failure to bind the TAP complex and to present virus-derived peptides to CTL. Immunity. 4:1996;505-514.
33. Ortmann B.et al. A critical role for tapasin in the assembly and function of multimeric class I-TAP complexes. Science. 277:1997;1306-1309.
34. Aridor M., Balch W.E. Integration of endoplasmic reticulum signaling in health and disease. Nat. Med. 5:1999;745-751.
35. Pahl H.L. Signal transduction from the endoplasmic reticulum to the cell nucleus. Physiol. Rev. 79:1999;683-701.
36. Baeuerle P.A., Henkel T. Function and activation of NF-κB in the immune system. Ann. Rev. Immunol. 12:1994;141-179.
37. Kitamura M. NF-κB-mediated self defense of macrophages faced with bacteria. Eur. J. Immunol. 29:1999;1647-1655.
38. Penttinen M.A.et al. MHC class I molecules modulate LPS-induced NF-κB activation in U937 human monocytic cells. Arthritis Rheum. 42:1999;S385.
39. 2-microglobulin-free heavy chain homodimer structure. J. Immunol. 162:1999;5045-5048.
40. 2-microglobulin dissociation. J. Immunol. 151:1993;159-169.
41. 2m. J. Clin. Invest. 98:1997;2746-2755.
42. Weinreich S.et al. HLA-B27 as a relative risk factor in ankylosing enthesopathy in transgenic mice. Hum. Immunol. 42:1995;103-115.
43. Zhou M.et al. The specificity of peptides bound to HLA-B27 influences the prevalence of arthritis in HLA-B27 transgenic rats. J. Exp. Med. 188:1998;877-886.
44. 2-microglobulin: a model of human spondyloarthropathies. J. Exp. Med. 182:1995;1153-1158.
45. Khare S.D.et al. Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: a direct role for B27 heavy chains and not B27-derived peptides. J. Immunol. 160:1998;101-106.
46. McNeil A.J.et al. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. Q. J. Med. 89:1996;177-185.